14.10.2015 • NewsChairmanDede Willamshealthcare

Stefan Oschmann to Head Germany’s Merck

Stefan Oschmann has been named as new chief executive of Germany’s Merck...
Stefan Oschmann has been named as new chief executive of Germany’s Merck KGaA, succeeding current CEO Karl-Ludwig Kley, who will retire following the German chemical and pharmaceutical producer’s annual general meeting on Apr. 29, 2016.

Stefan Oschmann has been named as new chief executive of Germany’s Merck KGaA, succeeding current CEO Karl-Ludwig Kley, who will retire following the German chemical and pharmaceutical producer’s annual general meeting on Apr. 29, 2016. A member of the Merck executive board since 2011, the 58-year-old manager was initially in charge of the pharmaceutical business. At the beginning of 2015, he was named deputy chairman and CEO, responsible for strategy and innovation.

During the nine-year tenure of the now 64-year-old Kley as head of Merck, the company has gone through the biggest transformation in its almost 350-year history, said Johannes Baillou, chairman of the Board of Partners at E. Merck, parent of the Merck group. 

From a company with a diverse portfolio in pharma and chemicals in 2006, Baillou noted that Merck has evolved into a specialized high-tech company in healthcare, life science and performance materials. Following mergers and acquisitions worth about €38 billion as well as organic growth, sales this year are expected to be twice the 2005 level. Two change programs have resulted in a leaner organization capable of driving innovation more efficiently.

Free Virtual Event

Sustainability in Bioprocessing
Bioprocess Forum

Sustainability in Bioprocessing

Join us to explore hot topics in sustainable bioprocessing like the industrial potential of enzymatic synthesis, innovative biocatalysis techniques, and the use of digital twins in bioprocessing.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.